SERPINE1 and type 2 diabetes mellitus: In this context, the current observation of differential changes in PAI-1 in young women with varying degrees of recent gestational dysglycemia raises the possibility that PAI-1 may be a very early biomarker for tracking progression towards the clinical manifestation of cardiometabolic risk in this patient population (i.e. T2DM and CVD).